Interleukin-1 inhibition and fatigue in primary sjögren's syndrome - a double blind, randomised clinical trial

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Norheim, Katrine Brække ^a   Harboe, Erna ^a   Gøransson, Lasse G ^a,b   Omdal, Roald ^a,b  

^a STAVANGER UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; ANTIMALARIAL AGENT; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; LEFLUNOMIDE; PLACEBO; PREDNISOLONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; THYROXINE; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG HALF LIFE; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; GASTROENTERITIS; HUMAN; INJECTION SITE REACTION; MALAISE; MALE; OUTCOME ASSESSMENT; PARALLEL DESIGN; PHYSICAL EXAMINATION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; SINGLE BLIND PROCEDURE; SJOEGREN SYNDROME; SKIN DISEASE; VISUAL ANALOG SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DEPRESSION; DRUG ANTAGONISM; METABOLISM; MIDDLE AGED;

ANIMALIA;

ADULT; AGED; AGED, 80 AND OVER; DEPRESSION; DOUBLE-BLIND METHOD; FATIGUE; FEMALE; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; MALE; MIDDLE AGED; SJOGREN'S SYNDROME;

EID: 84855568775     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0030123     Document Type: Article

References (38)

1. Fox RI, (2005) Sjogren's syndrome. Lancet 366: 321-31.
2. Gøransson L, Haldorsen K, Brun J, Harboe E, Jonsson M, et al. (2011) The point prevalence of clinically relevant primary Sjogren's syndrome in two Norwegian counties. Scand J Rheumatol 40: 221-4.
3. Salomonsson S, Jonsson MV, Skarstein K, Brokstad KA, Hjelmstrøm P, et al. (2003) Cellular basis of ectopic germinal center formation and autoantibody production in the target organ of patients with Sjogren's syndrome. Arthritis Rheum 48: 3187-201.
4. Ramos-Casals M, Tzioufas AG, Font J, (2005) Primary Sjogren's syndrome: new clinical and therapeutic concepts. Ann Rheum Dis 64: 347-54.
5. Bjerrum K, Prause JU, (1990) Primary Sjogren's syndrome: a subjective description of the disease. Clin Exp Rheumatol 8: 283-8.
6. Meijer JM, Meiners PM, Huddleston Slater JJ, Spijkervet FK, Kallenberg CG, et al. (2009) Health-related quality of life, employment and disability in patients with Sjogren's syndrome. Rheumatology 48: 1077-82.
7. Harboe E, Tjensvoll AB, Vefring HK, Gøransson LG, Kvaløy JT, et al. (2009) Fatigue in primary Sjogren's syndrome-a link to sickness behaviour in animals? Brain Behav Immun 23: 1104-8.
8. Bowman SJ, (2008) Patient-reported outcomes including fatigue in primary Sjogren's syndrome. Rheum Dis Clin North Am 34: 949-62, ix.
9. Ng WF, Bowman SJ, (2010) Primary Sjogren's syndrome: too dry and too tired. Rheumatology (Oxford) 49: 844-53.
10. Dantzer R, (2001) Cytokine-induced sickness behavior: where do we stand? Brain Behav Immun 15: 7-24.
11. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelly KW, (2008) From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 9: 46-56.
12. Kent S, Bret-Dibat JL, Kelley KW, Dantzer R, (1996) Mechanisms of sickness-induced decreases in food-motivated behavior. Neurosci Biobehav Rev 20: 171-5.
13. Bluthe RM, Laye S, Michaud B, Combe C, Dantzer R, et al. (2000) Role of interleukin-1beta and tumour necrosis factor-alpha in lipopolysaccharide-induced sickness behaviour: a study with interleukin-1 type I receptor-deficient mice. Eur J Neurosci 12: 4447-56.
14. Dinarello CA, (2010) IL-1: discoveries, controversies and future directions. Eur J Immunol 40: 599-606.
15. Arend WP, Malyak M, Guthridge CJ, Gabay C, (1998) Interleukin-1 receptor antagonist: role in biology. Annu Rev Immunol 16: 27-55.
16. Gutierrez EG, Banks WA, Kastin AJ, (1994) Blood-borne interleukin-1 receptor antagonist crosses the blood-brain barrier. J Neuroimmunol 55: 153-60.
17. Abraham J, Johnson RW, (2009) Central inhibition of interleukin-1beta ameliorates sickness behavior in aged mice. Brain Behav Immun 23: 396-401.
18. Dinarello CA, (1996) Biological basis for interleukin-1 in disease. Blood 87: 2095-2147.
19. Ogilvie AC, Hack CE, Wagstaff J, van Mierlo GJ, Erenberg AJ, et al. (1996) IL-1 beta does not cause neutrophil degranulation but does lead to IL- 6, IL-8, and nitrite/nitrate release when used in patients with cancer. J Immunol 156: 389-94.
20. Omdal R, Gunnarsson R, (2005) The effect of interleukin-1 blockade on fatigue in rheumatoid arthritis-a pilot study. Rheumatol Int 25: 481-4.
21. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, et al. (2002) Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61: 554-8.
22. Beck AT, Beamesderfer A, (1974) Assessment of depression: the depression inventory. Mod Probl Pharmacopsychiatry 7: 151-69.
23. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD, (1989) The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 46: 1121-3.
24. Segal B, Thomas W, Rogers T, Leon JM, Hughes P, et al. (2008) Prevalence, severity, and predictors of fatigue in subjects with primary Sjogren's syndrome. Arthritis Rheum 59: 1780-7.
25. Dass S, Bowman SJ, Vital EM, Ikeda K, Pease CT, et al. (2008) Reduction of fatigue in Sjogren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann Rheum Dis 67: 1541-4.
26. Goransson LG, Herigstad A, Tjensvoll AB, Harboe E, Mellgren SI, et al. (2006) Peripheral neuropathy in primary sjogren syndrome: a population-based study. Arch Neurol 63: 1612-5.
27. Kelley KW, Hutchison K, French R, Bluthe RM, Parnet P, et al. (1997) Central interleukin-1 receptors as mediators of sickness. Ann N Y Acad Sci 823: 234-46.
28. Dantzer R, Capuron L, Irwin MR, Miller AH, Ollat H, et al. (2008) Identification and treatment of symptoms associated with inflammation in medically ill patients. Psychoneuroendocrinology 33: 18-29.
29. Goldbach-Mansky R, Dailey NJ, Canna SW, Gelabert A, Jones J, et al. (2006) Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med 355: 581-92.
30. Hess A, Axmann R, Rech J, Finzel S, Heindl C, et al. (2011) Blockade of TNF-alpha rapidly inhibits pain responses in the central nervous system. Proc Natl Acad Sci U S A 108: 3731-6.
31. Quan N, Banks WA, (2007) Brain-immune communication pathways. Brain Behav Immun 21: 727-35.
32. Banks WA, Kastin AJ, Broadwell RD, (1995) Passage of cytokines across the blood-brain barrier. Neuroimmunomodulation 2: 241-8.
33. Sriwatanakul K, Kelvie W, Lasagna L, Calimlim JF, Weis OF, et al. (1983) Studies with different types of visual analog scales for measurement of pain. Clin Pharmacol Ther 34: 234-9.
34. Meijer JM, Meiners PM, Vissink A, Spijkervet FK, Abdulahad W, et al. (2010) Effectiveness of rituximab treatment in primary Sjogren's syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 62: 960-8.
35. Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, et al. (2006) Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 367: 29-35.
36. Capuron L, Miller AH, (2011) Immune system to brain signaling: neuropsychopharmacological implications. Pharmacol Ther 130: 226-38.
37. Altman DG, Bland JM, (1999) How to randomise. BMJ 319: 703-4.
38. Seror R, Mariette X, Bowman S, Baron G, Gottenberg JE, et al. (2010) Accurate detection of changes in disease activity in primary Sjogren's syndrome by the European League Against Rheumatism Sjogren's Syndrome Disease Activity Index. Arthritis Care Res (Hoboken) 62: 551-8.